Hiroyuki Takei1, Eun-Sook Lee, V Craig Jordan. 1. Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center, USA. QYQ05440@nifty.ne.jp
Abstract
BACKGROUND: The effects of antiestrogens on angiogenesis in breast cancer are not fully defined. In this study we investigated the in vitro effects of antiestrogens at different concentrations on vascular endothelial growth factor (VEGF) production in estrogen receptor (ER)-positive breast cancer cells. METHODS: The dose-dependent effects of 17beta-estradiol (E2), 4-hydroxytamoxifen (4OHT), and ICI182,780 were analyzed both with reference to growth rates and VEGF protein production using enzyme-linked immunosorbent assay (ELISA) in MCF-7 cells. RESULTS: E2 stimulated both the growth rates and VEGF production of MCF-7 cells in the same manner. Although 4OHT stimulated the growth rates as an agonistic effect in an estrogen-free media at levels ranging from 1 nM to 1 micro M, it did not stimulate VEGF expression at the same levels except for at 1 micro M. Although 4OHT had a weak agonistic effect on VEGF production at 1 micro M in an estrogen-free media, it significantly inhibited E2-stimulated VEGF production at the same level. A cytotoxic effect was observed with 10 micro M 4OHT that paradoxically caused a prominent increase in VEGF production. ICI182,780 had no significant effects on the growth rates or VEGF production in this cell line. CONCLUSIONS: These results support the hypothesis that tamoxifen could inhibit angiogenesis induced by estrogens in ER-positive breast cancer cells.
BACKGROUND: The effects of antiestrogens on angiogenesis in breast cancer are not fully defined. In this study we investigated the in vitro effects of antiestrogens at different concentrations on vascular endothelial growth factor (VEGF) production in estrogen receptor (ER)-positive breast cancer cells. METHODS: The dose-dependent effects of 17beta-estradiol (E2), 4-hydroxytamoxifen (4OHT), and ICI182,780 were analyzed both with reference to growth rates and VEGF protein production using enzyme-linked immunosorbent assay (ELISA) in MCF-7 cells. RESULTS: E2 stimulated both the growth rates and VEGF production of MCF-7 cells in the same manner. Although 4OHT stimulated the growth rates as an agonistic effect in an estrogen-free media at levels ranging from 1 nM to 1 micro M, it did not stimulate VEGF expression at the same levels except for at 1 micro M. Although 4OHT had a weak agonistic effect on VEGF production at 1 micro M in an estrogen-free media, it significantly inhibited E2-stimulated VEGF production at the same level. A cytotoxic effect was observed with 10 micro M 4OHT that paradoxically caused a prominent increase in VEGF production. ICI182,780 had no significant effects on the growth rates or VEGF production in this cell line. CONCLUSIONS: These results support the hypothesis that tamoxifen could inhibit angiogenesis induced by estrogens in ER-positive breast cancer cells.
Authors: Roshani R Patel; Surojeet Sengupta; Helen R Kim; Andres J Klein-Szanto; Jennifer R Pyle; Fang Zhu; Tianyu Li; Eric A Ross; Salewa Oseni; Joseph Fargnoli; V Craig Jordan Journal: Eur J Cancer Date: 2010-03-18 Impact factor: 9.162
Authors: Katherine W Reeves; Roberta B Ness; Roslyn A Stone; Joel L Weissfeld; Victor G Vogel; Robert W Powers; Francesmary Modugno; Jane A Cauley Journal: Cancer Causes Control Date: 2008-11-06 Impact factor: 2.506
Authors: Maura N Dickler; William T Barry; Constance T Cirrincione; Matthew J Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S Rugo; Diana E Lake; Olwen Hahn; Bryan P Schneider; Debasish Tripathy; Lisa A Carey; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2016-05-02 Impact factor: 44.544
Authors: Tiffany A Traina; Hope S Rugo; James F Caravelli; Sujata Patil; Benjamin Yeh; Michele E Melisko; John W Park; Stephanie Geneus; Matthew Paulson; Jill Grothusen; Andrew D Seidman; Monica Fornier; Diana Lake; Chau Dang; Mark Robson; Maria Theodoulou; Carlos D Flombaum; Larry Norton; Clifford A Hudis; Maura N Dickler Journal: J Clin Oncol Date: 2009-10-19 Impact factor: 44.544